A day after the stock plummeted, it bounced back.
Investors didn't like the drugmaker's Q4 update.
BCRX earnings call for the period ending December 31, 2022.
BioCryst (BCRX) delivered earnings and revenue surprises of -100% and 6.11%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
BioCryst (BCRX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Ionis Pharmaceuticals (IONS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioCryst (BCRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neurocrine (NBIX) delivered earnings and revenue surprises of -23.48% and 0.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
The mean of analysts' price targets for BioCryst (BCRX) points to a 47.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts...
